Real-Time Margin Measurement
for Precision Cancer Surgery
Navigation Sciences is developing the NaviSci™ system to address the growing need to locate and remove lung and other soft tissue cancers.
- Reduce early-stage cancer recurrence risk
- Conserve lung function
- Improve surgical workflow
- Shorten hospital length of stay
NaviSci’s first application is in early-stage lung cancer, where there are more than 76,000 new cases each year in the U.S.; the number is growing annually due to increasing adoption of CT x-ray screening.
Overall, there are approximately 450,000 soft tissue cancer diagnoses annually in the U.S. where NaviSci has potential application.
Navigation Sciences™ Begins First-in-Human Clinical Feasibility Trial of its Pioneering, NaviSci™ System for Tissue-Conserving Removal of Early-Stage Lung Tumors Read more
Navigation Sciences initiates clinical feasibility study of the NaviSci™ System. Read more
Navigation Sciences receives approval from MassGeneral Brigham IRB to begin first in human clinical trial of NaviSci System. Read more
Navigation Sciences completes oversubscribed, $2.4 million Series A financing. Read more
FDA clears Navigation Sciences IDE for first clinical trial. Read more
Navigation Sciences raises $1.5 million seed round. Read more
NaviSci is based on technology developed by the company’s co-founders, leaders in thoracic surgery and advanced surgical navigation technology, Raphael Bueno, M.D., Chief, Thoracic Surgery, and Jayender Jagadeesan, Ph.D., Associate Professor of Radiology both at Brigham & Women’s Hospital and Harvard Medical School. View our leadership team